ETF Holdings Breakdown of COLL

Stock Name	Collegium Pharmaceutical Inc
Ticker	COLL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US19459J1043
LEI	54930049FXZMTLW8D496

News associated with COLL

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Ritholtz Wealth Management: Ritholtz Wealth Management lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 32,108 shares of the specialty pharmaceutical company’s stock after selling 1,676 shares during the quarter. Ritholtz Wealth Management’s holdings in Collegium Pharmaceutical were worth $958,000 as of its most […] - 2025-06-18 08:56:50
Exchange Traded Concepts LLC Decreases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Exchange Traded Concepts LLC cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 16.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,426 shares of the specialty pharmaceutical company’s stock after selling 12,669 shares during […] - 2025-06-18 08:18:59
Farther Finance Advisors LLC Raises Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Farther Finance Advisors LLC boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 4.5% in the first quarter, Holdings Channel.com reports. The institutional investor owned 11,091 shares of the specialty pharmaceutical company’s stock after acquiring an additional 477 shares during the period. Farther Finance Advisors LLC’s holdings in Collegium Pharmaceutical were worth […] - 2025-06-18 07:30:54
California State Teachers Retirement System Has $862,000 Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): California State Teachers Retirement System reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 30,093 shares of the specialty pharmaceutical company’s stock after selling 856 shares during the period. California State Teachers Retirement System’s holdings in Collegium Pharmaceutical were […] - 2025-06-11 08:04:51
Wellington Management Group LLP Lowers Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Wellington Management Group LLP reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,591 shares of the specialty pharmaceutical company’s stock after selling 26,049 shares during the period. Wellington Management Group […] - 2025-06-06 08:04:54
Bank of America Corp DE Trims Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Bank of America Corp DE decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 29.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 86,096 shares of the specialty pharmaceutical company’s stock after selling 36,093 shares during the period. Bank of America Corp DE’s holdings in Collegium Pharmaceutical were worth […] - 2025-06-02 07:38:48
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by ProShare Advisors LLC: ProShare Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 28.8% in the 4th quarter, Holdings Channel reports. The fund owned 11,196 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,506 shares during the quarter. ProShare Advisors LLC’s holdings in Collegium Pharmaceutical were worth $321,000 […] - 2025-05-30 08:06:52
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.80 Average Price Target from Brokerages: Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price […] - 2025-05-21 06:14:51
Voya Investment Management LLC Cuts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Voya Investment Management LLC lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 7.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,923 shares of the specialty pharmaceutical company’s stock after selling 789 shares during the period. Voya […] - 2025-05-13 07:32:48
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stake Reduced by Hsbc Holdings PLC: Hsbc Holdings PLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 16,879 shares of the specialty pharmaceutical company’s stock after selling 576 shares during the period. Hsbc Holdings PLC’s holdings in Collegium Pharmaceutical were worth $483,000 at the end […] - 2025-05-07 08:00:51
Barclays PLC Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Barclays PLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,754 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,702 shares during the […] - 2025-05-01 08:14:59
Raymond James Financial Inc. Buys New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Raymond James Financial Inc. bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 84,883 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,432,000. Other hedge funds and […] - 2025-04-30 08:10:55
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Legal & General Group Plc: Legal & General Group Plc lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 1.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 91,309 shares of the specialty pharmaceutical company’s stock after selling 1,084 shares during the period. Legal & General Group Plc’s holdings in Collegium Pharmaceutical were […] - 2025-04-24 09:31:01
Russell Investments Group Ltd. Decreases Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Russell Investments Group Ltd. reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 31.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,649 shares of the specialty pharmaceutical company’s stock after selling 6,223 shares […] - 2025-04-24 07:48:48
JPMorgan Chase & Co. Cuts Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): JPMorgan Chase & Co. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 70.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 82,691 shares of the specialty pharmaceutical company’s stock after selling 194,513 shares during the […] - 2025-04-24 07:16:59
Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com: Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday. A number of other analysts also recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a […] - 2025-04-21 05:22:45
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Invesco Ltd.: Invesco Ltd. grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 19.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,775,760 shares of the specialty pharmaceutical company’s stock after acquiring an additional 289,335 shares during the quarter. Invesco Ltd. owned about […] - 2025-04-16 07:47:00
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at StockNews.com: StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a buy rating to a strong-buy rating in a research report report published on Friday morning. A number of other equities research analysts also recently weighed in on COLL. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on […] - 2025-04-14 05:58:57
Vanguard Group Inc. Sells 63,876 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Vanguard Group Inc. cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,282,666 shares of the specialty pharmaceutical company’s stock after selling 63,876 shares during the period. Vanguard Group Inc. […] - 2025-04-11 09:16:58
Corebridge Financial Inc. Sells 1,595 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Corebridge Financial Inc. lowered its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 8.5% during the 4th quarter, HoldingsChannel reports. The fund owned 17,084 shares of the specialty pharmaceutical company’s stock after selling 1,595 shares during the period. Corebridge Financial Inc.’s holdings in Collegium Pharmaceutical were worth $489,000 as of its […] - 2025-04-09 07:38:48
American Century Companies Inc. Has $2.45 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): American Century Companies Inc. trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 18.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,466 shares of the specialty pharmaceutical company’s stock after selling 19,447 […] - 2025-04-08 08:04:48
Thrivent Financial for Lutherans Has $714,000 Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Thrivent Financial for Lutherans lessened its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 1.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 24,928 shares of the specialty pharmaceutical company’s stock after selling 369 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Collegium Pharmaceutical were worth $714,000 at […] - 2025-04-03 07:16:47
25,700 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $736,000. A number […] - 2025-04-02 08:44:53
HighTower Advisors LLC Has $428,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): HighTower Advisors LLC cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,956 shares of the specialty pharmaceutical company’s stock after selling 441 shares during the quarter. HighTower Advisors […] - 2025-04-01 07:28:44
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Brokerages: Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has received a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts […] - 2025-04-01 05:24:51
Amundi Has $446,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Amundi lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 188.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,568 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,168 shares during the period. Amundi’s holdings in Collegium Pharmaceutical were worth $446,000 as of its most […] - 2025-03-21 07:58:58
Victory Capital Management Inc. Reduces Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Victory Capital Management Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 21.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 559,536 shares of the specialty pharmaceutical company’s stock after selling 151,152 shares during the period. Victory […] - 2025-03-13 08:32:56
Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Price Target at $43.60: Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 […] - 2025-03-07 06:25:02
Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.60: Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective […] - 2025-02-14 09:18:55
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Choreo LLC: Choreo LLC trimmed its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,401 shares of the specialty pharmaceutical company’s stock after selling 630 shares during the quarter. Choreo LLC’s holdings in Collegium […] - 2025-02-14 08:42:49

COLL institutional holdings

The following institutional investment holdings of COLL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 26,688 USD 797,971

2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 4,003 USD 119,690

2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 16,355 USD 489,015

2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 16,355 USD 489,015

2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 329 USD 9,837

Total = 63,730 USD 1,905,528
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	26,688	USD 797,971
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	4,003	USD 119,690
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	16,355	USD 489,015
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	16,355	USD 489,015
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	329	USD 9,837
Total =	63,730	USD 1,905,528

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.